Replies to post #156483 on Biotech Values

[oc631]

I’m not as cynical as oc631, so I don’t think GILD is seeking to profit by treating many genotype-3 patients twice rather than once.

You are putting words in my mouth. I didn't say retreatment was part of GILD's overall strategy. This situation is a result of GILD's shortcomings in HCV in-house development and the combo should not be approved for GT3.